RARE
HEALTHCAREUltragenyx
AI Insight
What's Moving RARE Today?
No stock-specific AI insight has been generated for RARE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$18.29$42.37
$28.76
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-6.10
Dividend Yield—
Dividend / Share—
ROE-608.0%
Profit Margin-90.9%
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding98.5M
RARE News
38 articles- Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of DirectorsYahoo Finance·Jun 23, 2026
- Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman SyndromeUltragenyx·Jun 20, 2026
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Jun 19, 2026
- Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip StocksYahoo Finance·Jun 13, 2026
- How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street ViewsYahoo Finance·Jun 6, 2026
- Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street ZenMarketBeat·Jun 6, 2026
- Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)Yahoo Finance·Jun 5, 2026
- Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Jun 4, 2026
- Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·Jun 3, 2026
- What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One YearMotley Fool·May 30, 2026
- Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook By Investing.comInvesting.com Canada·May 21, 2026
- [Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading ActivityStock Titan·May 18, 2026
- Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesYahoo Finance·May 12, 2026
- Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses?Yahoo Finance·May 11, 2026
- Ultragenyx to Participate at Bank of America’s 2026 Healthcare ConferenceYahoo Finance·May 6, 2026
- RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal EffectYahoo Finance·May 6, 2026
- Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Ultragenyx Pharmaceutical Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 5, 2026
- Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- Ultragenyx Reports First Quarter 2026 Financial Results and Corporate UpdateYahoo Finance·May 5, 2026
- Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should KnowYahoo Finance·Apr 29, 2026
- Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman TrialYahoo Finance·Apr 29, 2026
- Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate UpdateYahoo Finance·Apr 29, 2026
- ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the FirmGlobeNewswire Inc.·Apr 6, 2026
- TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages BlackRock TCP Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – TCPCGlobeNewswire Inc.·Apr 5, 2026
- RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RAREGlobeNewswire Inc.·Apr 5, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 1, 2026
- Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Apr 1, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREOGlobeNewswire Inc.·Mar 31, 2026
- Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. InvestorsGlobeNewswire Inc.·Mar 31, 2026
- POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - POMGlobeNewswire Inc.·Mar 30, 2026
- RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RAREGlobeNewswire Inc.·Mar 30, 2026
- INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD LawGlobeNewswire Inc.·Mar 29, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Mar 29, 2026
- Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RAREGlobeNewswire Inc.·Mar 26, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Mar 25, 2026
- Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Mar 25, 2026
All 38 articles loaded
Price Data
Open$28.58
Previous Close$29.03
Day High$29.39
Day Low$28.50
52 Week High$42.37
52 Week Low$18.29
52-Week Range
$18.29$42.37
$28.76
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-6.10
Dividend Yield—
Dividend / Share—
ROE-608.0%
Profit Margin-90.9%
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding98.5M
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—